Injectable contraception

Seminars in Reproductive Medicine

Volumn 28, Issue 2, 2010, Pages 126-132

  Roy, Geneviève ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Depo Provera; Depot medroxyprogesterone acetate; Injectable contraception; Medroxyprogesterone acetate

Indexed keywords

DANAZOL; INJECTABLE CONTRACEPTIVE AGENT; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ASTHENIA; BIRTH CONTROL; BLEEDING; BONE DENSITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTRACEPTION; DIZZINESS; DRUG MECHANISM; ENDOMETRIOSIS; HEADACHE; HUMAN; METABOLIC DISORDER; NERVOUSNESS; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; TREATMENT CONTRAINDICATION;

BONE DENSITY; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS; MEDROXYPROGESTERONE ACETATE; RISK ASSESSMENT;

EID: 77950531619     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0030-1248137     Document Type: Review

References (75)

1. Paschall S, Kaunitz A M. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians. Contraception 2008 78 (5) 370-376
2. Mishell D R. Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996 41 (5, Suppl) 381-390
3. Prabhakaran S. Self-administration of injectable contraceptives. Contraception 2008 77 (5) 315-317
4. Kaunitz A M. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 1994 170 (5 Pt 2) 1543-1549
5. Trussell J. Contraceptive failure in the United States. Contraception 2004 70 89-96
6. Jain J, Jakimiuk A J., Bode F R., Ross D, Kaunitz A M. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004 70 (4) 269-275
7. Petta C A., Faundes A, Dunson T R. et al. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus. Fertil Steril 1998 69 (2) 252-257
8. Lopez L M., Newmann S J., Grimes D A., Nanda K, Schulz K F. Immediate start of hormonal contraceptives for contraception. Cochrane Database Syst Rev 2008 2 (2) CD006260
9. Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill M S. Pregnancies diagnosed during Depo-Provera use. Contraception 2002 66 (3) 169-172
10. Steiner M J., Kwok C, Stanback J et al. Injectable contraception: what should the longest interval be for reinjections? Contraception 2008 77 (6) 410-414
11. Belsey E M. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Adv Contracept 1991 7 (23) 257-270
12. Kaunitz A M. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996 41 (5, suppl) 419-427
13. Cullins V E. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 1996 41 (5, suppl) 428-433
14. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani P G. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996 175 (2) 396-401
15. Crosignani P G., Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006 21 (1) 248-256 (Pubitemid 41794318)
16. Schlaff W D., Carson S A., Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006 85 (2) 314-325 (Pubitemid 43170902)
17. De Ceulaer K, Gruber C, Hayes R, Serjeant G R. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 1982 2 (8292) 229-231
18. Mattson R H., Cramer J A., Caldwell B V., Siconolfi B C. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 1984 34 (9) 1255-1258
19. Frederiksen M C. Depot medroxyprogesterone acetate contraception in women with medical problems. J Reprod Med 1996 41 (5, suppl) 414-418
20. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004 11 (1) 11-33
21. Thomas D B., Ray R M., The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 1991 49 (2) 186-190
22. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. Lancet 1991 338 (8771) 833-838
23. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. Int J Cancer 1991 49 (2) 191-195
24. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. Contraception 1992 45 (4) 299-312
25. Skegg D C., Noonan E A., Paul C et al. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of World Health Organization and New Zealand studies. JAMA 1995 273 799-804
26. Shapiro S, Rosenberg L, Hoffman M et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000 151 (4) 396-403
27. Strom B L., Berlin J A., Weber A L. et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 2004 69 (5) 353-360
28. Schwallie P C., Assenzo J R. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 1974 10 (2) 181-202
29. Kahn H S., Curtis K M., Marchbanks P A. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care 2003 26 (1) 216-225
30. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 1996 41 (5, suppl) 401-406 (Pubitemid 26172581)
31. Garza-Flores J, De la Cruz D L., Valles de Bourges V et al. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 1991 44 (1) 61-71
32. Enk L, Landgren B M., Lindberg U B., Silfverstolpe G, Crona N. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992 24 (2) 85-89
33. Graff-Iversen S, Tonstad S. Use of progestogen-only contraceptives/ medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey. Contraception 2002 66 (1) 7-13
34. Sorensen M B., Collins P, Ong P J. et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002 106 (13) 1646-1651
35. Kaunitz A M. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2003 107 (9) e67-e68; author reply e67e68
36. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998 57 (5) 315-324
37. Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Use of hormonal contraception in women with coexisting medical conditions, number 23. Obstet Gynecol 2006 107 (6) 1453-1472
38. Clark M K., Sowers M, Levy B T., Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 2001 75 (5) 871-877
39. Karlsson M K., Ahlborg H G., Karlsson C. Maternity and bone mineral density. Acta Orthop 2005 76 (1) 2-13
40. Kalkwarf H J. Lactation and maternal bone health. Adv Exp Med Biol 2004 554 101-114
41. Kalkwarf H J., Specker B L. Bone mineral changes during pregnancy and lactation. Endocrine 2002 17 (1) 49-53
42. Curtis K M., Martins S L. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 2006 73 (5) 470-487
43. Cromer B A., Bonny A E., Stager M et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril 2008 90 (6) 2060-2067
44. Kaunitz A M., Darney P D., Ross D, Wolter K D., Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 2009 80 (1) 7-17
45. Kaunitz A M., Miller P D., Rice V M., Ross D, McClung M R. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006 74 (2) 90-99
46. Scholes D, LaCroix A Z., Ichikawa L E., Barlow W E., Ott S M. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002 13 (5) 581-587
47. Kaunitz A M., Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008 77 (2) 67-76
48. Rosenberg L, Zhang Y, Constant D et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception 2007 76 (6) 425-431
49. Kaunitz A M., Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008 77 (2) 67-76
50. Scholes D, LaCroix A Z., Ichikawa L E., Barlow W E., Ott S M. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002 13 (5) 581-587
51. Orr-Walker B J., Evans M C., Ames R W., Clearwater J M., Cundy T, Reid I R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 1998 49 (5) 615-618
52. Cundy T, Cornish J, Roberts H, Reid I R. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol 2002 186 (5) 978-983
53. Scholes D, LaCroix A Z., Ichikawa L E., Barlow W E., Ott S M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005 159 (2) 139-144
54. Schlaff W D., Carson S A., Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006 85 (2) 314-325 (Pubitemid 43170902)
55. Crosignani P G., Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006 21 (1) 248-256 (Pubitemid 41794318)
56. World Health Organization. Department of Reproductive Health and Research. WHO statement on hormonal contraception and bone health. Wkly Epidemiol Rec 2005 80 302-304
57. The National Collaborating Centre for Women's and Children's Health. Long-Acting Reversible ContraceptionClinical Guideline 30. London, United Kingdom National Institute for Health and Clinical Excellence 2005 1-176
58. Cromer B A., Scholes D, Berenson A, Cundy T, Clark M K., Kaunitz A M., Society for Adolescent Medicine. Depot medroxyprogesterone acetate and bone mineral density in adolescentsthe Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 2006 39 (2) 296-301
59. Black A, Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada. Canadian contraception consensusupdate on depot medroxyprogesterone acetate (DMPA). J Obstet Gynaecol Can 2006 28 (4) 305-313
60. Cundy T, Ames R, Horne A et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 2003 88 (1) 78-81
61. Cromer B A., Lazebnik R, Rome E et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 2005 192 (1) 42-47
62. Belsey E M. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988 38 (2) 181-206
63. Kaunitz A M. Menstruation: choosing whether.. and when. Contraception 2000 62 (6) 277-284
64. Glasier A F., Smith K B., van der Spuy Z M. et al. Amenorrhea associated with contraceptionan international study on acceptability. Contraception 2003 67 (1) 1-8
65. Abdel-Aleem H, d'Arcangues C, Vogelsong K, Gulmezoglu A M. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007 (4) CD003449
66. Mainwaring R, Hales H A., Stevenson K et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception 1995 51 (3) 149-153
67. Moore L L., Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 1995 52 (4) 215-219
68. Risser W L., Gefter L R., Barratt M S., Risser J M. Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999 24 (6) 433-436
69. Danli S, Qingxiang S, Guowei S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception 2000 62 (1) 15-18
70. Espey E, Steinhart J, Ogburn T, Qualls C. Depo-Provera associated with weight gain in Navajo women. Contraception 2000 62 (2) 55-58
71. Templeman C, Boyd H, Hertweck S P. Depomedroxyprogesterone acetate use and weight gain among adolescents. J Pediatr Adolesc Gynecol 2000 13 (1) 45-46
72. Mangan S A., Larsen P G., Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2002 15 (2) 79-82
73. Berenson A B., Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol 2009 200 (3) 329 e1e8
74. Schwallie P, Assenzo J R. Conctraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973 24 (5) 331-339
75. Bjrn I, Bixo M, Njd K S., Nyberg S, Bckstrm T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000 183 (6) 1419-1426